The case for & against
Bull & Bear analysis
Bearish
Sara Prognostics, Inc. (NASDAQ: SARA) is a pioneer in prenatal screening solutions aimed at improving maternal and neonatal health outcomes through innovative risk assessment technologies for preterm births. The company operates primarily within the healthcare sector, focusing on diagnostics related to pregnancy care. As SARA transitions from R&D phase towards commercialization, it is establishing significant partnerships with Medicaid to facilitate reimbursement pathways while addressing the pressing issue of preterm births—a major public health concern in the U.S. and globally.
Bull says
- ↑Q1 2025 revenue jumped from $0 to $38k
- ↑Pilot programs active with ten payers across 13 states
- ↑Cash position of $86.8M funds operations into 2029
- ↑Potential $1,600 per member cost savings strengthen payer negotiations
- ↑PRIME study publication may boost payer adoption and credibility
- ↑Positive asset quality factors and rising Medicaid engagement
Bear says
- ↓Q1 2026 revenue plunged to $14k, down from $38k
- ↓Net loss widened to $8.4M with $9.4M operating expenses
- ↓Sales and marketing spend rose to $6.3M, pressuring cash
- ↓Profitability and earnings factors remain weak, dampening investor appeal
- ↓Guideline inclusion may take 24–36 months, delaying scale adoption
- ↓Complex Medicaid pilot logistics heighten execution and timing risks
Earnings Call · Q1 2026 · Mgmt. Guidance
Updated 05-12-2026bullish
Transcript signals
Bull points
- we expect to support our long-term volume and revenue. Adding to our two live programs, we launched our third partnership program during the quarter, further expanding education and access to preterm. This program is expected to reach over 350 providers across three states, expanding our clinical footprint and advancing earlier identification and intervention for at-risk pregnancies.
- Together, these publications support our stakeholder engagement efforts in Europe and underscore the global relevance of risk-based preterm birth prevention as healthcare systems increasingly emphasize prevention, education, and cost-effective maternal care.
- We also recently launched a targeted letter-writing campaign designed to encourage physicians and patients to engage with state Medicaid programs on reimbursement for the preterm test.
Bear points
- Revenue for the quarter was $14,000 compared to $38,000 in the first quarter of 2025.
- Net loss for the quarter was $8.4 million compared to a net loss of $8.2 million in the first quarter of 2025.
- we realized that we need less capacity specifically for our preterm birth product R&D.
Read full transcript analysis ›